Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7IW9J)

Drug Name
Ramelteon Drug Info
Synonyms
Rozerem; Ramelteon [USAN]; Rozerem (TN); TAK-375; Ramelteon (JAN/USAN/INN); Rozerem, TAK-375, Ramelteon; N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide; N-{2-[(8s)-1,6,7,8-tetrahydro-2h-indeno[5,4-b]fur-8-yl]ethyl}propanamid; (-)-N-(2-(((8S)-1,6,7,8-Tetrahydro-2H-indeno(5,4-b)furan-8-yl)ethyl)propanamide; (S)-N-(2-(1,6,7,8-tetrahydro-2H-indeno-(5,4)furan-8-yl)ethyl)propionamide
Indication
Disease Entry ICD 11 Status REF
Insomnia 7A00-7A0Z Approved [1]
Circadian rhythm sleep disorder 7A60-7A65 Terminated [1]
Therapeutic Class
Hypnotics and Sedatives
Cross-matching ID
PubChem CID
208902
ChEBI ID
CHEBI:109549
CAS Number
CAS 196597-26-9
TTD Drug ID
DM7IW9J
INTEDE Drug ID
DR1391
ACDINA Drug ID
D00581

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Melatonin receptor type 1B (MTNR1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tasimelteon DMLOQ1V Insomnia 7A00-7A0Z Approved [6]
VLB-01 DMQGV5P Epilepsy 8A60-8A68 Phase 3 [7]
2-iodo-melatonin DMSEIUP Discovery agent N.A. Investigative [8]
N-(2,3,4,9-Tetrahydro-1H-carbazol-3-yl)-acetamide DMWC70I Discovery agent N.A. Investigative [9]
5-methoxycarbonylamino-N-acetyltryptamine DMCZSP3 Discovery agent N.A. Investigative [10]
N-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide DMLWGPC Discovery agent N.A. Investigative [11]
Beta-methylmelatonin DMKH32S Discovery agent N.A. Investigative [12]
UCM-454 DMSVJFG Discovery agent N.A. Investigative [13]
N-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide DMILWPS Discovery agent N.A. Investigative [11]
N-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide DMHM0WI Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Melatonin receptor type 1A (MTNR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Melatonin DMKWFBT Depression 6A70-6A7Z Approved [14]
Tasimelteon DMLOQ1V Insomnia 7A00-7A0Z Approved [6]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [15]
LY-156735 DM5IX9M Anxiety disorder 6B00-6B0Z Phase 2 [16]
Agomelatine DMXYA5K Major depressive disorder 6A70.3 Withdrawn from market [17]
Luzindole DMXRJQV Sleep-wake disorder 7A00-7B2Z Terminated [18]
S-20928 DMQDWMJ Sleep-wake disorder 7A00-7B2Z Terminated [19]
GR-133347 DMNRJA0 Anxiety disorder 6B00-6B0Z Terminated [20]
GR-131663 DMKAGLV Anxiety disorder 6B00-6B0Z Terminated [21]
SL-18.1616 DMI1WNF Insomnia 7A00-7A0Z Terminated [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [23]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [24]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [25]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [26]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [27]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [28]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [29]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [30]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [24]
Verapamil DMA7PEW Angina pectoris BA40 Approved [31]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [32]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [33]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [34]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [35]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [36]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [37]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [29]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [38]
Verapamil DMA7PEW Angina pectoris BA40 Approved [39]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [40]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [41]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [42]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [43]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [44]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [45]
Verapamil DMA7PEW Angina pectoris BA40 Approved [46]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [47]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [48]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [49]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [50]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Retinal dehydrogenase 2 (ALDH1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [5]
Polyethylene glycol DM4I1JP Constipation DD91.1 Approved [5]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [5]
Panobinostat DM58WKG Chronic graft versus host disease Approved [51]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [5]
Nilotinib DM7HXWT Chronic myelogenous leukaemia 2A20.0 Approved [5]
Disulfiram DMCL2OK Alcohol dependence 6C40.2 Approved [52]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [53]
Dabigatran DMDI6R4 Stroke 8B20 Approved [5]
Metoclopramide DMFA5MY Nausea MD90 Approved [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Homeobox protein Hox-B7 (HOXB7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [54]
Polyethylene glycol DM4I1JP Constipation DD91.1 Approved [5]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [5]
Nilotinib DM7HXWT Chronic myelogenous leukaemia 2A20.0 Approved [5]
Testosterone enanthate DMB6871 N. A. N. A. Approved [55]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [56]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [57]
Abacavir DMMN36E Human immunodeficiency virus infection 1C62 Approved [5]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [5]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [58]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Paired box protein Pax-6 (PAX6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [54]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [5]
Panobinostat DM58WKG Chronic graft versus host disease Approved [51]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [5]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [59]
Nilotinib DM7HXWT Chronic myelogenous leukaemia 2A20.0 Approved [5]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [60]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [61]
Dabigatran DMDI6R4 Stroke 8B20 Approved [5]
Folic Acid DMEMBJC Colorectal carcinoma Approved [62]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Homeobox protein MOX-1 (MEOX1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [63]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [5]
Polyethylene glycol DM4I1JP Constipation DD91.1 Approved [5]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [5]
Panobinostat DM58WKG Chronic graft versus host disease Approved [51]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [64]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [5]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [65]
Nilotinib DM7HXWT Chronic myelogenous leukaemia 2A20.0 Approved [5]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [53]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Fibroblast growth factor 8 (FGF8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [66]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [54]
Panobinostat DM58WKG Chronic graft versus host disease Approved [51]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [5]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [53]
Dolutegravir DMCZGRE Human immunodeficiency virus infection 1C62 Approved [67]
Dabigatran DMDI6R4 Stroke 8B20 Approved [5]
Folic Acid DMEMBJC Colorectal carcinoma Approved [68]
Abacavir DMMN36E Human immunodeficiency virus infection 1C62 Approved [5]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Mesoderm posterior protein 2 (MESP2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [5]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [5]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [5]
Nilotinib DM7HXWT Chronic myelogenous leukaemia 2A20.0 Approved [5]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [5]
Abacavir DMMN36E Human immunodeficiency virus infection 1C62 Approved [5]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [5]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [69]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Affected By Oligodendrocyte transcription factor 3 (OLIG3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [5]
Polyethylene glycol DM4I1JP Constipation DD91.1 Approved [5]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [5]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [5]
Nilotinib DM7HXWT Chronic myelogenous leukaemia 2A20.0 Approved [5]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [62]
Dabigatran DMDI6R4 Stroke 8B20 Approved [5]
Ethanol DMDRQZU Chronic pain MG30 Approved [70]
Abacavir DMMN36E Human immunodeficiency virus infection 1C62 Approved [5]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Eyes absent homolog 1 (EYA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [71]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [72]
Polyethylene glycol DM4I1JP Constipation DD91.1 Approved [5]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [5]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [5]
Nilotinib DM7HXWT Chronic myelogenous leukaemia 2A20.0 Approved [5]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [5]
Dabigatran DMDI6R4 Stroke 8B20 Approved [5]
Abacavir DMMN36E Human immunodeficiency virus infection 1C62 Approved [5]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melatonin receptor type 1A (MTNR1A) TT0WAIE MTR1A_HUMAN Modulator [2]
Melatonin receptor type 1B (MTNR1B) TT32JK8 MTR1B_HUMAN Modulator [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [3]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [4]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Eyes absent homolog 1 (EYA1) OTHU807A EYA1_HUMAN Gene/Protein Processing [5]
Fibroblast growth factor 8 (FGF8) OTFU0IUW FGF8_HUMAN Gene/Protein Processing [5]
Homeobox protein Hox-B7 (HOXB7) OTC7WYU8 HXB7_HUMAN Gene/Protein Processing [5]
Homeobox protein MOX-1 (MEOX1) OTJEMT2D MEOX1_HUMAN Gene/Protein Processing [5]
Homeobox protein unc-4 homolog OTOW7WTS UNC4_HUMAN Gene/Protein Processing [5]
Mesoderm posterior protein 2 (MESP2) OT7H4LYA MESP2_HUMAN Gene/Protein Processing [5]
Oligodendrocyte transcription factor 3 (OLIG3) OTU8XLAF OLIG3_HUMAN Gene/Protein Processing [5]
Paired box protein Pax-6 (PAX6) OTOC9876 PAX6_HUMAN Gene/Protein Processing [5]
Protein Wnt-5a OT27ZYKJ WNT5A_HUMAN Gene/Protein Processing [5]
Retinal dehydrogenase 2 (ALDH1A2) OTJB560Z AL1A2_HUMAN Gene/Protein Processing [5]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1356).
2 MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85.
3 Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91.
4 Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications. J Cent Nerv Syst Dis. 2011 Apr 12;3:51-65.
5 Exposure-based assessment of chemical teratogenicity using morphogenetic aggregates of human embryonic stem cells. Reprod Toxicol. 2020 Jan;91:74-91. doi: 10.1016/j.reprotox.2019.10.004. Epub 2019 Nov 8.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393).
7 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8 Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3). J Med Chem. 2002 Apr 25;45(9):1853-9.
9 Mapping the melatonin receptor. 2. synthesis and biological activity of indole derived melatonin analogues with restricted conformations of the C-3 amidoethane side chain, Bioorg. Med. Chem. Lett. 4(13):1559-1564 (1994).
10 Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3. Bioorg Med Chem. 2008 May 1;16(9):4954-62.
11 Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
12 Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-me... J Med Chem. 2006 Jun 15;49(12):3509-19.
13 2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem. 2009 Feb 12;52(3):826-33.
14 The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J Neuroendocrinol. 2005 Mar;17(3):170-8.
15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 288).
16 Melatonin and sleep in aging population. Exp Gerontol. 2005 Dec;40(12):911-25.
17 Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr Top Med Chem. 2008;8(11):954-68.
18 Luzindole (N-0774): a novel melatonin receptor antagonist. J Pharmacol Exp Ther. 1988 Sep;246(3):902-10.
19 Effects of two melatonin analogues, S-20098 and S-20928, on melatonin receptors in the pars tuberalis of the rat. J Pineal Res. 1998 Oct;25(3):172-6.
20 US patent application no. 5,151,446, Substituted 2-amidotetralins as melatonin agonists and antagonists.
21 Novel non-indolic melatonin receptor agonists differentially entrain endogenous melatonin rhythm and increase its amplitude. Eur J Pharmacol. 1999 Oct 15;382(3):157-66.
22 US patent application no. 2005,016,4987, Melatonin combination therapy for improving sleep quality.
23 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
24 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
25 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
26 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
27 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
28 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
29 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
30 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
31 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
32 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
33 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
34 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
35 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
36 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
37 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
38 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
39 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
40 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
41 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
42 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
43 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
44 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
45 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
46 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
47 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
48 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
49 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
50 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
51 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
52 The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chem Biol Interact. 2012 Jan 5;195(1):52-60.
53 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
54 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
55 Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
56 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
57 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
58 Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
59 hiPSC-Based Model of Prenatal Exposure to Cannabinoids: Effect on Neuronal Differentiation. Front Mol Neurosci. 2020 Jul 6;13:119. doi: 10.3389/fnmol.2020.00119. eCollection 2020.
60 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
61 Epigenetic changes and disturbed neural development in a human embryonic stem cell-based model relating to the fetal valproate syndrome. Hum Mol Genet. 2012 Sep 15;21(18):4104-14. doi: 10.1093/hmg/dds239. Epub 2012 Jun 20.
62 Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792. doi: 10.1016/j.taap.2021.115792. Epub 2021 Nov 3.
63 Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
64 Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
65 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
66 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
67 Dolutegravir Impairs Stem Cell-Based 3D Morphogenesis Models in a Manner Dependent on Dose and Timing of Exposure: An Implication for Its Developmental Toxicity. Toxicol Sci. 2021 Nov 24;184(2):191-203. doi: 10.1093/toxsci/kfab112.
68 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
69 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
70 Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
71 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
72 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.